Table 5. Important or game changing products proposed by the Commission on Investing in Health that could help achieve a grand convergence in global health by 2035.

	Diagnostics	Drugs	Vaccines
Short term (available before 2020)
Important	POC diagnostics for HIV, TB, malaria; POC vital load for HIV	New artemisinin co-formulations for malaria; new TB drug co-formulations *; curative drugs for hepatitis C; new antivirals for influenza; long-acting contraceptive implant; safe, effective, shorter duration therapy for active and latent TB; new drugs for NTDs * (with high efficacy and few side effects)	Moderately efficacious (50%) malaria vaccine; conjugated typhoid vaccine; staphylococcal vaccine; heat-stable vaccines; new adjuvants to reduce multiple dosing of vaccines; more effective influenza vaccines in elderly people
Potentially game-changing		Single encounter treatment for malaria: a one-dose cure for vivax and falciparum
Medium term (available before 2030)
Important		Antimicrobials based on a new mechanism of action	Combined diarrhea vaccine * (rotavirus, enterotoxigenic E. coli, typhoid, shigella); protein-based universal pneumococcal vaccine; RSV vaccine; hepatitis C vaccine *
Potentially game-changing		New classes of antiviral drugs	HIV vaccine *; TB vaccine *; highly efficacious malaria vaccine *; universal influenza vaccine

Abbreviations: POC: point-of-care; NTDs: neglected tropical diseases; RSV: respiratory syncytial virus; TB: tuberculosis

*The 18 “missing” products based on modeling the current pipeline (vaccines against HIV, TB, malaria, and hepatitis C; combined vaccine against multiple diarrheal diseases; complex NCE for TB; NCEs for 12 NTDs (based on the WHO list of NTDs at http://www.who.int/neglected_diseases/mediacentre/factsheet/en).